Tenofovir
- Generic Name
- Tenofovir
- Brand Names
- Vemlidy, Tenofovir disoproxil Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H14N5O4P
- CAS Number
- 147127-20-6
- Unique Ingredient Identifier
- W4HFE001U5
- Background
Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in ...
- Indication
Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.
To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, tenofovir alafenamide and tenofovir disoproxil.
- Associated Conditions
- -
- Associated Therapies
- -
From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients
- Conditions
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-03-06
- Target Recruit Count
- 36
- Registration Number
- NCT06295328
- Locations
- 🇳🇱
Amsterdam UMC, Amsterdam, Noord-Holland, Netherlands
Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04539119
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, Shanghai, Shanghai, China
Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 70
- Registration Number
- NCT04431375
- Locations
- 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, Delhi, India
Nucleosides And Darunavir/Dolutegravir In Africa
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 465
- Registration Number
- NCT03988452
- Locations
- 🇺🇬
Infectious Diseases Institute, Kampala, Uganda
The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Wits Health Consortium (Pty) Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT03986970
- Locations
- 🇿🇦
The Perinatal HIV Research Unit, Johannesburg, Gauteng, South Africa
Effect on HIV Medications on EPC Cells
- Conditions
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Sabyasachi Sen
- Target Recruit Count
- 22
- Registration Number
- NCT03782142
- Locations
- 🇺🇸
The GW Medical Faculty Associates, Washington, District of Columbia, United States
Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT03759782
- Locations
- 🇨🇦
Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Single Dose Truvada Study
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 44
- Registration Number
- NCT03719053
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D
- Conditions
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Hepatera Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03546621
- Locations
- 🇩🇪
Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany
🇷🇺State Autonomous Healthcare Institution "Republican Clinical Infectious Diseases Hospital named after Prof. A.F. Agafonov "(SAHI RCID), Kazan, Russian Federation
🇷🇺State Budget Health Institution of Moscow "Infectious Clinical Hospital No. 1 of the Moscow Healthcare Department", Moscow, Russian Federation
Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract
- Conditions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 28
- Registration Number
- NCT03218085
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.